These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23764045)

  • 1. The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.
    Kerl K; Ries D; Unland R; Borchert C; Moreno N; Hasselblatt M; Jürgens H; Kool M; Görlich D; Eveslage M; Jung M; Meisterernst M; Frühwald M
    BMC Cancer; 2013 Jun; 13():286. PubMed ID: 23764045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
    Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia.
    Sun X; Hasanali ZS; Chen A; Zhang D; Liu X; Wang HG; Feith DJ; Loughran TP; Xu K
    Br J Haematol; 2015 Feb; 168(3):371-83. PubMed ID: 25284154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.
    Shi XY; Ding W; Li TQ; Zhang YX; Zhao SC
    Med Sci Monit; 2017 Dec; 23():5793-5802. PubMed ID: 29211704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
    Unland R; Borchardt C; Clemens D; Kool M; Dirksen U; Frühwald MC
    Anticancer Drugs; 2015 Mar; 26(3):301-11. PubMed ID: 25415657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vorinostat and fenretinide synergize in preclinical models of T-cell lymphoid malignancies.
    Makena MR; Nguyen TH; Koneru B; Hindle A; Chen WH; Verlekar DU; Kang MH; Reynolds CP
    Anticancer Drugs; 2021 Jan; 32(1):34-43. PubMed ID: 33079733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosmarinic Acid, a Component of Rosemary Tea, Induced the Cell Cycle Arrest and Apoptosis through Modulation of HDAC2 Expression in Prostate Cancer Cell Lines.
    Jang YG; Hwang KA; Choi KC
    Nutrients; 2018 Nov; 10(11):. PubMed ID: 30453545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin.
    Jin JS; Tsao TY; Sun PC; Yu CP; Tzao C
    Pathol Oncol Res; 2012 Jul; 18(3):713-20. PubMed ID: 22270866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
    Modesitt SC; Parsons SJ
    Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.
    Murahari S; Jalkanen AL; Kulp SK; Chen CS; Modiano JF; London CA; Kisseberth WC
    BMC Cancer; 2017 Jan; 17(1):67. PubMed ID: 28109246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.
    Bhatt S; Ashlock BM; Toomey NL; Diaz LA; Mesri EA; Lossos IS; Ramos JC
    J Clin Invest; 2013 Jun; 123(6):2616-28. PubMed ID: 23635777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
    Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
    Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells.
    Lee YJ; Won AJ; Lee J; Jung JH; Yoon S; Lee BM; Kim HS
    Int J Med Sci; 2012; 9(10):881-93. PubMed ID: 23155362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL.
    Yerbes R; López-Rivas A
    Invest New Drugs; 2012 Apr; 30(2):541-7. PubMed ID: 21107885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
    Nidhyanandan S; Thippeswamy BS; Chandrasekhar KB; Reddy ND; Kulkarni NM; Karthikeyan K; Khan FR; Raghul J; Vijaykanth G; Narayanan S
    Anticancer Drugs; 2017 Oct; 28(9):1002-1017. PubMed ID: 28727579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suberanilohydroxamic acid (vorinostat) synergistically enhances the cytotoxicity of doxorubicin and cisplatin in osteosarcoma cell lines.
    Pettke A; Hotfilder M; Clemens D; Klco-Brosius S; Schaefer C; Potratz J; Dirksen U
    Anticancer Drugs; 2016 Nov; 27(10):1001-10. PubMed ID: 27487911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.
    Cheung BB; Tan O; Koach J; Liu B; Shum MS; Carter DR; Sutton S; Po'uha ST; Chesler L; Haber M; Norris MD; Kavallaris M; Liu T; O'Neill GM; Marshall GM
    Mol Oncol; 2015 Aug; 9(7):1484-500. PubMed ID: 25963741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.